Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]
ApprovedRecruiting 0 views this week 0 watching⚡ Active
Interest: 50/100
50
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Eosinophilic Esophagitis (EoE)
Conditions
Eosinophilic Esophagitis (EoE)
Trial Timeline
Nov 10, 2024 → Nov 14, 2026
NCT ID
NCT06665971About Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]
Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT] is a approved stage product being developed by Regeneron Pharmaceuticals for Eosinophilic Esophagitis (EoE). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06665971. Target conditions include Eosinophilic Esophagitis (EoE).
What happened to similar drugs?
5 of 16 similar drugs in Eosinophilic Esophagitis (EoE) were approved
Approved (5) Terminated (2) Active (9)
Hype Score Breakdown
Clinical
20
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06665971 | Approved | Recruiting |
Competing Products
20 competing products in Eosinophilic Esophagitis (EoE)